Difference between revisions of "Part:BBa K3335003"

 
Line 1: Line 1:
 +
__NOTOC__
 +
<partinfo>BBa_K3335003 short</partinfo>
  
 +
We used it to express iRGD-Lamp2b and siRNA targeted at KRAS Lung cancer is the major cause of cancer-related deaths globally. Mutant KRAS is a feature of 15%–50% of lung cancer cases[1]. Unfortunately, although much effort has been spent on searching for small molecule inhibitors of KRAS, KRAS gene has proven extraordinarily difficult to target by current pharmacological agents.
 +
 +
This year we developed an alternative strategy to silence the so-called untargetable and undruggable KRAS gene by employing exosome-mediated siRNA delivery.At the same time, we used iRGDLamp2b to achieve exosome targeting. Particularly, we reprogrammed cells to simultaneously express KRAS siRNA and Lamp2b. Lamp2b is an exosomal membrane protein, in fusion with a tumor-penetrating internalizing RGD (iRGD) peptide (CRGDKGPDC), and then produce the tumor-targeting exosomes as KRAS siRNA delivery
 +
system.[1]
 +
 +
With this system, we can target tumor cells and deliver siRNA.
 +
 +
[1]Yu Zhou et al.,Tumor-specific delivery of KRAS siRNA with iRGD-exosomes efficiently inhibits tumor growth. ExRNA,2019.
 +
 +
<!-- Add more about the biology of this part here -->
 +
===Usage and Biology===
 +
 +
<!-- -->
 +
<span class='h3bb'>Sequence and Features</span>
 +
<partinfo>BBa_K3335000 SequenceAndFeatures</partinfo>
 +
 +
 +
<!-- Uncomment this to enable Functional Parameter display -->
 +
===Functional Parameters===
 +
<partinfo>BBa_K3335000 parameters</partinfo>
 +
hello world
 +
<!-- -->

Revision as of 08:49, 22 October 2020

We used it to express iRGD-Lamp2b and siRNA targeted at KRAS

We used it to express iRGD-Lamp2b and siRNA targeted at KRAS Lung cancer is the major cause of cancer-related deaths globally. Mutant KRAS is a feature of 15%–50% of lung cancer cases[1]. Unfortunately, although much effort has been spent on searching for small molecule inhibitors of KRAS, KRAS gene has proven extraordinarily difficult to target by current pharmacological agents.

This year we developed an alternative strategy to silence the so-called untargetable and undruggable KRAS gene by employing exosome-mediated siRNA delivery.At the same time, we used iRGDLamp2b to achieve exosome targeting. Particularly, we reprogrammed cells to simultaneously express KRAS siRNA and Lamp2b. Lamp2b is an exosomal membrane protein, in fusion with a tumor-penetrating internalizing RGD (iRGD) peptide (CRGDKGPDC), and then produce the tumor-targeting exosomes as KRAS siRNA delivery system.[1]

With this system, we can target tumor cells and deliver siRNA.

[1]Yu Zhou et al.,Tumor-specific delivery of KRAS siRNA with iRGD-exosomes efficiently inhibits tumor growth. ExRNA,2019.

Usage and Biology

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal BglII site found at 335
    Illegal BglII site found at 2999
    Illegal BamHI site found at 246
    Illegal BamHI site found at 442
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal BsaI site found at 435
    Illegal BsaI site found at 2598
    Illegal BsaI.rc site found at 1920
    Illegal BsaI.rc site found at 2644


Functional Parameters

hello world